BridgeBio Oncology Therapeutics, Inc.
BBOTHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, BridgeBio Oncology Therapeutics, Inc. focuses on Biotechnology services and products. BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and. The $213.3M market capitalization puts BBOT squarely in micro-cap range for its industry. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Market Cap
$213.3M
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
-0.96
EPS (TTM)
$-0.07
EPS (Fwd)
$-2.76
ROE
-81.9%
ROA
-47.1%
Cash
$225.7M
Total Debt
$2.5M
Free CF
-$90.0M
52W Change
-76.5%
Annual Financials
Cash vs Debt
Where BBOT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BBOT finished 63.04% below its 150-day moving average ($7.71) and 66.71% below its 200-day moving average ($8.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BBOT overbought or oversold?
At the October 20, 2026 close, BBOT's RSI(14) was 16.1, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $225.7M in cash comfortably exceeding the $2.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$90.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -81.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.65 suggests BBOT is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BridgeBio Oncology Therapeutics, Inc.'s trajectory.